Mustang Bio, a clinical-stage biopharmaceutical firm, focuses on licensed immunotherapies targeting difficult solid tumors with CAR T-cell (MB-101) and oncolytic virus (MB-108) programs. Despite accumulated losses nearing $398.6 million and ongoing negative cash flow of $5.26 million in 2025, the company has bolstered liquidity through equity offerings and warrant exercises to extend its runway. Regulatory dynamics, including FDA orphan drug designations and review of MB-109 combination therapy, present critical inflection points. Mustang faces capital constraints, regulatory complexities, and reliance on exclusive licensing partnerships, shaping a high-risk developmental trajectory.